These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 11261748

  • 1. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy.
    Pal S, Bhattacharya KF, Agapito C, Chaudhuri KR.
    J Neural Transm (Vienna); 2001; 108(1):71-7. PubMed ID: 11261748
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group.
    Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J.
    JAMA; 2001; 287(4):455-63. PubMed ID: 11798367
    [Abstract] [Full Text] [Related]

  • 6. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
    Inzelberg R, Schechtman E, Nisipeanu P.
    Drugs Aging; 2003; 20(11):847-55. PubMed ID: 12964891
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bedtime cabergoline in Parkinson's disease patients with excessive daytime sleepiness induced by dopamine agonists.
    Del Dotto P, Gambaccini G, Caneparo D, Berti C, Bernardini S, Bonuccelli U.
    Neurol Sci; 2003 Oct; 24(3):170-1. PubMed ID: 14598071
    [Abstract] [Full Text] [Related]

  • 9. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
    Razmy A, Lang AE, Shapiro CM.
    Arch Neurol; 2004 Jan; 61(1):97-102. PubMed ID: 14732626
    [Abstract] [Full Text] [Related]

  • 10. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
    Etminan M, Samii A, Takkouche B, Rochon PA.
    Drug Saf; 2001 Jan; 24(11):863-8. PubMed ID: 11665873
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Sleepiness in Parkinson's disease: a controlled study.
    Brodsky MA, Godbold J, Roth T, Olanow CW.
    Mov Disord; 2003 Jun; 18(6):668-72. PubMed ID: 12784270
    [Abstract] [Full Text] [Related]

  • 13. Pramipexole-induced somnolence and episodes of daytime sleep.
    Hauser RA, Gauger L, Anderson WM, Zesiewicz TA.
    Mov Disord; 2000 Jul; 15(4):658-63. PubMed ID: 10928575
    [Abstract] [Full Text] [Related]

  • 14. Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study.
    Romigi A, Stanzione P, Marciani MG, Izzi F, Placidi F, Cervellino A, Giacomini P, Brusa L, Grossi K, Pierantozzi M.
    J Neural Transm (Vienna); 2006 Dec; 113(12):1909-13. PubMed ID: 16736238
    [Abstract] [Full Text] [Related]

  • 15. 'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect?
    Chaudhuri KR, Pal S, Brefel-Courbon C.
    Drug Saf; 2002 Dec; 25(7):473-83. PubMed ID: 12093305
    [Abstract] [Full Text] [Related]

  • 16. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole.
    Eggert K, Öhlwein C, Kassubek J, Wolz M, Kupsch A, Ceballos-Baumann A, Ehret R, Polzer U, Klostermann F, Schwarz J, Fuchs G, Jost W, Albert A, Haag A, Hermsen A, Lohmüller K, Kuhn K, Wangemann M, Oertel WH, In Cooperation With the German Competence Network on Parkinson’s Disease.
    Clin Neuropharmacol; 2014 Dec; 37(4):116-22. PubMed ID: 24992083
    [Abstract] [Full Text] [Related]

  • 17. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K, Needleman F, Macphee G, Grosset D.
    Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
    [Abstract] [Full Text] [Related]

  • 18. Excessive daytime sleepiness in parkinsonism.
    Arnulf I.
    Sleep Med Rev; 2005 Jun; 9(3):185-200. PubMed ID: 15893249
    [Abstract] [Full Text] [Related]

  • 19. Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers.
    Ferreira JJ, Desboeuf K, Galitzky M, Thalamas C, Brefel-Courbon C, Fabre N, Senard JM, Montastruc JL, Sampaio C, Rascol O.
    Eur J Neurol; 2006 Mar; 13(3):209-14. PubMed ID: 16618334
    [Abstract] [Full Text] [Related]

  • 20. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    Clin Neuropharmacol; 2008 Mar; 31(1):19-24. PubMed ID: 18303487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.